IL2 and neuroblastoma: Here, we report the results of a multicenter clinical study investigating the activity and safety of single-agent dinutuximab beta (i.e., without IL-2 or isotretinoin) administered by long-term, continuous infusion in patients with relapsed/refractory HR-NB.